Stock REPL REPLIMUNE GROUP, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Replimune Group, Inc.

Equities

REPL

US76029N1063

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-12 pm EDT 		5-day change 1st Jan Change
8.82 USD -2.00% Intraday chart for Replimune Group, Inc. +58.63% +4.63%
Jun. 07 HC Wainwright Adjusts Price Target on Replimune to $17 From $12, Maintains Buy Rating MT
Jun. 06 Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Replimune : Corporate Presentation June 2024
PU
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
AQ
Replimune : Primary Analysis of the IGNYTE Registrational Cohort Presentation June 2024
PU
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
AQ
Replimune : IGNYTE Oral Presentation at ASCO 2024
PU
Replimune : RP2 Uveal Melanoma Oral Presentation at ASCO 2024
PU
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
AQ
Replimune : Corporate Presentation May 2024
PU
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
AQ
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Replimune : Uveal Melanoma Biomarker Poster at AACR 2024
PU
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
AQ
Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
AQ
Replimune to Present at Three Upcoming Investor Conferences
AQ
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
AQ
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
AQ
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REPL Stock
  4. News Replimune Group, Inc.
  5. Press Releases